Faculty Opinions recommendation of Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.

2012 ◽  
Author(s):  
Steven Le Gouill ◽  
Cyrille Touzeau
Keyword(s):  
Multiple Myeloma ◽  
Phase Ii ◽  
Induction Therapy ◽  
Phase Ii Study ◽  
Randomized Phase Ii

Phase II study of cyclophosphamide, interferon-α and betamethasone (CIB) as induction therapy for patients 60–75 years of age with multiple myeloma stages II and III

2003 ◽  
Vol 4 (4) ◽  
pp. 248-252 ◽  
Author(s):  
Jeanette Lundin ◽  
Anders Österborg ◽  
Magnus Björkholm ◽  
Bo Björkstrand ◽  
Fredrik Celsing ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase Ii ◽  
Induction Therapy ◽  
Phase Ii Study ◽  
Interferon Α

scholarly journals Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial

2017 ◽  
Vol 179 (4) ◽  
pp. 586-597 ◽  
Author(s):  
Hermann Einsele ◽  
Monika Engelhardt ◽  
Christoph Tapprich ◽  
Jürgen Müller ◽  
Peter Liebisch ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase Ii ◽  
Induction Therapy ◽  
Phase Ii Study

Elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma: A randomized phase II study.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 8014-8014 ◽  
Author(s):  
P. G. G. Richardson ◽  
P. Moreau ◽  
A. J. Jakubowiak ◽  
T. Facon ◽  
S. Jagannath ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase Ii ◽  
Low Dose ◽  
Phase Ii Study ◽  
Randomized Phase Ii

Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: a randomised phase II-study

2003 ◽  
Vol 70 (6) ◽  
pp. 379-383 ◽  
Author(s):  
Bo Björkstrand ◽  
Thomas Rasmussen ◽  
Kari Remes ◽  
Astrid Gruber ◽  
Tarja-Terttu Pelliniemi ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase Ii ◽  
Induction Therapy ◽  
Phase Ii Study
Sign in / Sign up

Export Citation Format

Share Document